Department of Mathematics and Statistics, University of Turku, Turku, Finland.
Institute of Biomedicine, University of Turku, Turku, Finland.
Sci Rep. 2017 Jul 26;7(1):6600. doi: 10.1038/s41598-017-06544-x.
Organotypic, three-dimensional (3D) cancer models have enabled investigations of complex microtissues in increasingly realistic conditions. However, a drawback of these advanced models remains the poor biological relevance of cancer cell lines, while higher clinical significance would be obtainable with patient-derived cell cultures. Here, we describe the generation and data analysis of 3D microtissue models from patient-derived xenografts (PDX) of non-small cell lung carcinoma (NSCLC). Standard of care anti-cancer drugs were applied and the altered multicellular morphologies were captured by confocal microscopy, followed by automated image analyses to quantitatively measure phenotypic features for high-content chemosensitivity tests. The obtained image data were thresholded using a local entropy filter after which the image foreground was split into local regions, for a supervised classification into tumor or fibroblast cell types. Robust statistical methods were applied to evaluate treatment effects on growth and morphology. Both novel and existing computational approaches were compared at each step, while prioritizing high experimental throughput. Docetaxel was found to be the most effective drug that blocked both tumor growth and invasion. These effects were also validated in PDX tumors in vivo. Our research opens new avenues for high-content drug screening based on patient-derived cell cultures, and for personalized chemosensitivity testing.
器官型,三维(3D)癌症模型使人们能够在越来越真实的条件下研究复杂的微组织。然而,这些先进模型的一个缺点仍然是癌细胞系的生物学相关性较差,而通过患者来源的细胞培养可以获得更高的临床意义。在这里,我们描述了从非小细胞肺癌(NSCLC)患者来源异种移植物(PDX)生成和分析 3D 微组织模型的方法。标准的抗癌药物被应用,通过共聚焦显微镜捕获改变的多细胞形态,然后通过自动图像分析对表型特征进行定量测量,以进行高内涵化学敏感性测试。使用局部熵滤波器对获得的图像数据进行阈值处理,然后将图像前景分割成局部区域,进行监督分类,分为肿瘤或成纤维细胞类型。应用稳健的统计方法来评估治疗对生长和形态的影响。在每个步骤中都比较了新的和现有的计算方法,同时优先考虑高实验通量。多西他赛被发现是最有效的药物,它可以阻断肿瘤生长和侵袭。这些作用也在体内的 PDX 肿瘤中得到了验证。我们的研究为基于患者来源的细胞培养的高内涵药物筛选和个性化化学敏感性测试开辟了新的途径。